Axcella is designing novel compositions of endogenous metabolic modulators to research and develop powerful (1) new medicines with the goal of addressing metabolic dysregulation by safely reprogramming cellular physiology with unprecedented multifactorial effects and (2) new consumer health† products that support the normal structure and function of the body. Our AXA™ product candidates are designed to leverage the diversity and synergy of amino acid biology to maintain or restore health across a network of pathways.
We are committed to researching and developing pioneering treatments for patients with unmet needs, and consumer health† products. Our AXA candidates are designed, optimized and studied using our platform. This innovative paradigm integrates preclinical studies and data from Non-IND clinical studies in a rapid, iterative process to generate candidates with a higher probability of success in a highly capital efficient manner. Our platform has already produced a rich pipeline of product candidates including programs in liver, muscle, CNS and other targets in development.
*Axcella conducts Non-IND, IRB-approved food studies to evaluate the safety and tolerability of its AXA candidates in human subjects, or effects on the normal structure or function of the body. Studies intended to directly support drug development will be conducted under an IND.
